Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RPID (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 37.64% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 115.87M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 666290 | Beta 1.1 | 52 Weeks Range 0.58 - 4.04 | Updated Date 04/1/2025 |
52 Weeks Range 0.58 - 4.04 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -167.16% | Operating Margin (TTM) -124.47% |
Management Effectiveness
Return on Assets (TTM) -25.83% | Return on Equity (TTM) -48.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69580861 | Price to Sales(TTM) 4.13 |
Enterprise Value 69580861 | Price to Sales(TTM) 4.13 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 38737200 | Shares Floating 10072852 |
Shares Outstanding 38737200 | Shares Floating 10072852 | ||
Percent Insiders 9.26 | Percent Institutions 54.42 |
Analyst Ratings
Rating 5 | Target Price 8 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems, Inc. was founded in 2006. It focuses on developing and providing automated microbial detection systems for the pharmaceutical, biotechnology, and personal care product industries. The company has evolved from its initial focus on automating traditional microbial testing methods to offering solutions that enhance accuracy, efficiency, and data integrity.
Core Business Areas
- Growth Direct System: The Growth Direct system automates and accelerates microbial detection and enumeration, replacing traditional manual methods. It is used for quality control testing of non-sterile and sterile pharmaceutical products.
- Consumables and Services: Rapid Micro Biosystems provides consumables specifically designed for use with the Growth Direct system, as well as services including validation, training, and support to ensure optimal system performance and customer satisfaction.
Leadership and Structure
The leadership team consists of executives with experience in microbiology, engineering, and pharmaceutical industries. The organizational structure includes departments for research and development, manufacturing, sales and marketing, customer support, and administration.
Top Products and Market Share
Key Offerings
- Growth Direct System: The Growth Direct system is their primary product. It is an automated system for rapid microbial detection and enumeration. There are no exact market share figures readily available as this market is a sub-segment of the overall microbiology testing and automation market. Competitors include bioMu00e9rieux (BIM.PA), Charles River Laboratories (CRL), and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for rapid and automated microbial testing solutions due to regulatory requirements, increasing production volumes, and the need for faster time-to-results. The market is driven by the pharmaceutical, biotechnology, and personal care product industries.
Positioning
Rapid Micro Biosystems is positioned as a provider of innovative, automated microbial detection systems that improve efficiency and data integrity compared to traditional methods. Their competitive advantage lies in their proprietary Growth Direct technology.
Total Addressable Market (TAM)
The TAM for rapid microbial testing is estimated to be in the billions of dollars. Rapid Micro Biosystems is positioned to capture a share of this market by providing solutions that offer advantages in terms of speed, accuracy, and data management. No figures available for exact TAM amount.
Upturn SWOT Analysis
Strengths
- Proprietary Growth Direct technology
- Automated system improves efficiency and data integrity
- Focus on pharmaceutical, biotechnology, and personal care product industries
- Strong customer support and service
Weaknesses
- High initial cost of system implementation
- Limited product portfolio compared to larger competitors
- Reliance on specific consumables for system operation
Opportunities
- Expanding into new geographical markets
- Developing new applications for Growth Direct technology
- Offering integrated data management solutions
- Partnering with pharmaceutical and biotechnology companies
Threats
- Competition from larger, more established companies
- Changes in regulatory requirements
- Technological advancements by competitors
- Economic downturns affecting capital spending by customers
Competitors and Market Share
Key Competitors
- BIM.PA
- CRL
- TMO
Competitive Landscape
Rapid Micro Biosystems has an advantage in its Growth Direct technology, which offers speed and automation benefits. However, it faces stiff competition from larger, more established companies like Charles River Laboratories, bioMu00e9rieux, and Thermo Fisher Scientific, which have broader product portfolios and greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires access to financial reports over several years. It generally focuses on revenue growth and market penetration.
Future Projections: Future projections are typically based on analyst estimates, which involve modeling market growth, competitive dynamics, and company-specific factors. Needs financial information to be completed.
Recent Initiatives: Recent initiatives might include new product development, strategic partnerships, and geographic expansion.
Summary
Rapid Micro Biosystems offers innovative automation solutions for microbial detection, primarily serving the pharmaceutical and biotech industries. Its Growth Direct technology is a key strength, but it faces strong competition from larger, well-established players. Future growth depends on expanding its market reach, developing new applications, and managing regulatory changes. The company's success hinges on further penetration of existing markets and careful management of its financial health, especially as a smaller player against larger competitors.
Similar Companies
CRL
Charles River Laboratories
CRL
Charles River Laboratories
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market share estimates are approximate and based on available data. Exact financials were not available for this query.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.